{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:39:42Z","timestamp":1790005182855,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00280-018-3677-6","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:25:41Z","timestamp":1535675141000},"page":"847-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers"],"prefix":"10.1007","volume":"82","author":[{"given":"Vassilios","family":"Aslanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lomeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Grosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Ouatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"3677_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","volume":"27","author":"CL Erickson-Miller","year":"2009","unstructured":"Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM (2009) Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27:424\u2013430","journal-title":"Stem Cells"},{"key":"3677_CR2","unstructured":"PROMACTA\u00ae (eltrombopag) [package insert]. Novartis Pharmaceuticals Co. East Hanover, NJ. \n                    https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/promacta.pdf\n                    \n                  . Accessed 29 Aug 2018"},{"key":"3677_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373:641\u2013648","journal-title":"Lancet"},{"key":"3677_CR4","unstructured":"REVOLADE\u00ae (eltrombopag): [summary of product characteristics]. Novartis Europharm Ltd. Dublin, Ireland. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/001110\/WC500089964.pdf\n                    \n                  . Accessed 22 Aug 2018"},{"key":"3677_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/0091270010375427","volume":"51","author":"E Gibiansky","year":"2011","unstructured":"Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D (2011) Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 51:842\u2013856","journal-title":"J Clin Pharmacol"},{"key":"3677_CR6","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","volume":"109","author":"JM Jenkins","year":"2007","unstructured":"Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739\u20134741","journal-title":"Blood"},{"key":"3677_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS (2017) Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376:1540\u20131550","journal-title":"N Engl J Med"},{"key":"3677_CR8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1177\/0091270010385934","volume":"51","author":"S Rebello","year":"2011","unstructured":"Rebello S, Compain S, Feng A, Hariry S, Dieterich HA, Jarugula V (2011) Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol 51:1549\u20131560","journal-title":"J Clin Pharmacol"},{"key":"3677_CR9","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1021\/jm300212s","volume":"55","author":"M Karlgren","year":"2012","unstructured":"Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55:4740\u20134763","journal-title":"J Med Chem"},{"key":"3677_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00280-005-0173-6","volume":"58","author":"A Gupta","year":"2006","unstructured":"Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374\u2013383","journal-title":"Cancer Chemother Pharmacol"},{"key":"3677_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2125.2010.03646.x","volume":"70","author":"G Matthys","year":"2010","unstructured":"Matthys G, Park JW, McGuire S, Wire MB, Zhang J, Bowen C, Williams D, Jenkins JM, Peng B (2010) Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol 70:24\u201333","journal-title":"Br J Clin Pharmacol"},{"key":"3677_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/dmd.106.011866","volume":"35","author":"CQ Xia","year":"2007","unstructured":"Xia CQ, Liu N, Miwa GT, Gan LS (2007) Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576\u2013582","journal-title":"Drug Metab Dispos"},{"key":"3677_CR13","unstructured":"NEORAL\u00ae (cyclosporine) [package insert]. Novartis Pharmaceuticals Co. East Hanover, NJ. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050715s027,050716s028lbl.pdf\n                    \n                  . Accessed 22 Aug 2018"},{"issue":"1","key":"3677_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.18433\/jpps29856","volume":"21","author":"DV Neves","year":"2018","unstructured":"Neves DV, Vieira CP, Rocha A, Lanchote VL (2018) Therapeutic doses of eltrombopag do not inhibit hepatic BCRP in healthy volunteers: intravenous ceftriaxone as a model. J Pharm Pharm Sci 21(1):236\u2013246","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"3677_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","volume":"72","author":"AJ Allred","year":"2011","unstructured":"Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, Lee E (2011) Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol 72(2):321\u2013329","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3677_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1124\/dmd.115.066795","volume":"44","author":"R Elsby","year":"2016","unstructured":"Elsby R, Martin P, Surry D, Sharma P, Fenner K (2016) Solitary Inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos 44(3):398\u2013408","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3677_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","volume":"31","author":"DD Williams","year":"2009","unstructured":"Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, Collins DA, Kapsi SG, Jenkins JM (2009) Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 31(4):764\u2013776","journal-title":"Clin Ther"},{"issue":"6","key":"3677_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1124\/dmd.110.037960","volume":"39","author":"K Takeuchi","year":"2011","unstructured":"Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y (2011) Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos 39(6):1088\u20131096","journal-title":"Drug Metab Dispos"},{"key":"3677_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1023\/A:1018923912135","volume":"11","author":"EA Mueller","year":"1994","unstructured":"Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K (1994) Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 11:301\u2013304","journal-title":"Pharm Res"},{"key":"3677_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF03190040","volume":"24","author":"PA Kelly","year":"1999","unstructured":"Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24:321\u2013328","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"3677_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00228-009-0716-6","volume":"66","author":"J Jenkins","year":"2009","unstructured":"Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS (2009) Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 66(1):67\u201376","journal-title":"Eur J Clin Pharmacol"},{"key":"3677_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1128\/AAC.05214-11","volume":"56","author":"MB Wire","year":"2012","unstructured":"Wire MB, McLean HB, Pendry C, Theodore D, Park JW, Peng B (2012) Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother 56:2846\u20132851","journal-title":"Antimicrob Agents Chemother"},{"key":"3677_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1572-0241.2007.01718.x","volume":"103","author":"MB Sternthal","year":"2008","unstructured":"Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH (2008) Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 103:937\u2013943","journal-title":"Am J Gastroenterol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3677-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3677-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3677-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T03:41:38Z","timestamp":1568950898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3677-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3677"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3677-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"VA, TO, and KG are employees of Novartis. JZ is an employee of PAREXEL International. BL is an employee of Quintiles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}